THE IMPACT OF SELECTED PSYCHOACTIVE SUBSTANCES - COCAINE, AMPHETAMINE, PSILOCYBIN, MDMA, AND KETAMINE - ON THE BODY IN PHYSICAL AND PSYCHOLOGICAL ASPECTS AND THEIR MAIN MECHANISMS OF ACTION: A NARRATIVE REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6082Keywords:
Cocaine, Amphetamine, Ecstasy, Psilocybin, NeurotoxicityAbstract
The article aims to compare receptor mechanisms related to neurotransmitters for some of the most widely used psychoactive substances - amphetamine, cocaine, ecstasy (MDMA), and psilocybin - and to link these mechanisms to cardiovascular effects, thermoregulation, and neurotoxicity. The review is based mainly on in vitro studies on transporters and receptors, animal models, and controlled clinical trials in humans. Amphetamine is a substrate for NET/DAT and VMAT2, inducing reverse monoamine transport and their release into the synapse, particularly norepinephrine and dopamine, leading to subsequent sympathomimetic effects and oxidative stress. Cocaine acts primarily as an inhibitor of monoamine reuptake via DAT/NET/SERT, with similar affinity for all three, which markedly increases DA/NA/5-HT levels and is associated with a high risk of cardiotoxicity. MDMA combines releasing and reuptake-inhibiting properties, with preference for SERT/NET, producing strong 5-HT efflux and empathogenic effects, but also hyperthermia, cardiovascular disturbances, and, in animal models, persistent serotonergic neurotoxicity involving oxidative stress and glutamate-mediated excitotoxicity. Psilocybin (psilocin) acts mainly as a 5-HT2A agonist, with contributions from 5-HT1A/2C receptors and neurotrophin receptors, promoting neuroplasticity and beneficial behavioral effects with relatively low acute somatic toxicity and moderate, transient hemodynamic changes in healthy volunteers. Overall, although all substances modulate the monoaminergic system, psychostimulants carry substantially higher cardiovascular and neurotoxic risk than psilocybin, which shows a favorable safety profile under controlled conditions.
References
Docherty J.R., Alsufyani H. Pharmacology of Drugs Used as Stimulants. Journal of Clinical Pharmacology. 2021;61(8):1063–1079. https://doi.org/10.1002/jcph.1859.
Rothman R.B., Baumann M.H. Monoamine transporters and psychostimulant drugs. European Journal of Pharmacology. 2003;479(1–3):23–40. https://doi.org/10.1016/j.ejphar.2003.08.054.
Sitte H.H., Freissmuth M. Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends in Pharmacological Sciences. 2015;36(1):41–50. https://doi.org/10.1016/j.tips.2014.11.006.
Støier J.F., Konomi-Pilkati A., Apuschkin M., Herborg F., Gether U. (2023). Amphetamine-induced reverse transport of dopamine does not require cytosolic Ca²⁺. The Journal of Biological Chemistry, 299(8): 104939. https://doi.org/10.1016/j.jbc.2023.104939.
Jones S.R., Gainetdinov R.R., Wightman R.M., Caron M.G. (1998). Mechanisms of Amphetamine Action Revealed in Mice Lacking the Dopamine Transporter. The Journal of Neuroscience, 18(6):1979–1986. https://doi.org/10.1523/JNEUROSCI.18-06-01979.1998.
Eiden L.E., Weihe E. (2011). VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Annals of the New York Academy of Sciences, 1216(1):86–98. https://doi.org/10.1111/j.1749-6632.2010.05906.x.
Robertson S.D., Matthies H.J.G., Galli A. (2009). A closer look at amphetamine induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Molecular Neurobiology, 39(2):73–80. https://doi.org/10.1007/s12035-009-8053-4.
Shaili Aggarwal, Ole Mortensen (2017). Overview of Monoamine Transporters. Current Protocols in Pharmacology, 79(1): 12.16.1–12.16.17. https://doi.org/10.1002/cpph.30.
Dawn D. Han, Howard H. Gu (2006). Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacology, 6:6. https://doi.org/10.1186/1471-2210-6-6.
James Eshleman, Melissa Carmolli, Michael Cumbay, Carey R. Martens, Kevin A. Neve, Aaron Janowsky (1999). Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. The Journal of Pharmacology and Experimental Therapeutics, 289(2):877–885.
Catherine Verrico, Gerald Miller, Bertha K. Madras, 2007, “MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment”, Psychopharmacology, Berlin: Springer. https://doi.org/10.1007/s00213-006-0555-9
Gary Rudnick, Stephen C. Wall, 1992, “The molecular mechanism of ‘ecstasy’ [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release”, Proceedings of the National Academy of Sciences of the USA, Washington (DC): National Academy of Sciences. https://doi.org/10.1073/pnas.89.5.1817
Larraitz Lizarraga, Aram B. Cholanians, Andy V. Phan, Joseph M. Herndon, Stephen S. Lau, Terrence A. Monks, 2014, “Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)-methylenedioxymethamphetamine”, Toxicological Sciences, Oxford: Oxford University Press. https://doi.org/10.1093/toxsci/kfu238
[ Sonia Sonda, Diana Pendin, Silvia Comai, Sara De Martin, Paolo L. Manfredi, Andrea Mattarei, 2025, Emerging mechanisms of psilocybin-induced neuroplasticity, Trends in Pharmacological Sciences, Amsterdam: Elsevier. https://doi.org/10.1016/j.tips.2024.07.004
Makiath Adebo, Marie Bonnet, Ons Laouej, Claire Defaix, Josephine C. McGowan, Florence Butlen-Ducuing, David David, Erwan Poupon, Lucile Tritschler, Alain M. Gardier, 2025, Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms, Fundamental & Clinical Pharmacology, Oxford: Wiley. https://doi.org/10.1111/fcp.13102
João Paulo Capela, Helena Carmo, Fátima Remião, Maria de Lourdes Bastos, Alexander Meisel, Félix Carvalho, 2009, Molecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview, Molecular Neurobiology, New York: Springer. https://doi.org/10.1007/s12035-009-8064-1
Desislava Popova, Andréas N. P. Forsblad, Sanaz Hashemian, Sven Ove Jacobsson, 2016, Non-Serotonergic Neurotoxicity by MDMA (Ecstasy) in Neurons Derived from Mouse P19 Embryonal Carcinoma Cells, PLOS ONE, San Francisco: Public Library of Science. https://doi.org/10.1371/journal.pone.0166750
Friederike Holze, Lisa Ley, Friederike Müller, Anna M. Becker, Isabelle Straumann, Patrick Vizeli, Sven Kuehne, Mads A. Røder, Urs Duthaler, Karolina E. Kolaczynska, Neha Varghese, Andrea Eckert, Matthias E. Liechti, 2022, „Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects”, Neuropsychopharmacology, London: Nature Publishing Group, https://doi.org/10.1038/s41386-021-01252-6.
Martin K. Madsen, Patrick M. Fisher, Daniel Burmester, Agnete Dyssegaard, Dea S. Stenbæk, Sara Kristiansen, Sys S. Johansen, Sczabolcs Lehel, Kristian Linnet, Claus Svarer, David Erritzoe, Brice Ozenne, Gitte M. Knudsen, 2019, „Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels”, Neuropsychopharmacology, London: Nature Publishing Group, https://doi.org/10.1038/s41386-018-0277-9.
Natalie Hesselgrave, Timothy A. Troppoli, Andreas B. Wulff, Anthony B. Cole, Scott M. Thompson, 2021, „Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice”, Proceedings of the National Academy of Sciences of the United States of America (PNAS), Washington (DC): National Academy of Sciences, https://doi.org/10.1073/pnas.2022489118.
Rosario Moratalla, Amit Khairnar, Nicola Simola, Noemí Granado, José-Rubén García-Montes, Pier Francesca Porceddu, Yousef Tizabi, Giulia Costa, Monica Morelli, 2017, “Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms”, Progress in Neurobiology, Amsterdam: Elsevier, https://doi.org/10.1016/j.pneurobio.2016.10.007.
Jennifer M. Mitchell, Michael P. Bogenschutz, Alia Lilienstein, Candice Harrison, Sarah E. Kleiman i in., 2021, „MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study”, Nature Medicine, New York, NY: Springer Nature, https://doi.org/10.1038/s41591-021-01336-3
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Klaudia Karolina Wójcik, Michał Kieres, Krzysztof Sebastian Habirek , Maja Maria Porażko , Anna Katarzyna Żurakowska-Zadrożna , Adrianna Krupska , Julia Anna Czarnecka , Zuzanna Marta Marcinkowska , Joanna Zuzanna Gugulska , Anna Kropiwnicka , Aleksander Kacper Kierys , Michał Mieczysław Parus
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
